Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

by Brana, Irene, Siu, Lillian L
Published 2012

Approaches to modernize the combination drug development paradigm

by Day, Daphne, Siu, Lillian L.
Published 2016

Understanding the attitudes of the elderly towards enrolment into cancer clinical trials

by Townsley, Carol A, Chan, Kelvin K, Pond, Gregory R, Marquez, Christine, Siu, Lillian L, Straus, Sharon E
Published 2006

Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital

by Ho, Jeremy, Pond, Gregory R, Newman, Colin, Maclean, Martha, Chen, Eric X, Oza, Amit M, Siu, Lillian L
Published 2006

Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer

by Aung, Kyaw L., Stockley, Tracy L., Serra, Stefano, Kamel-Reid, Suzanne, Bedard, Philippe L., Siu, Lillian L.
Published 2016

Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

by Kotasek, Dusan, Tebbutt, Niall, Desai, Jayesh, Welch, Stephen, Siu, Lillian L, McCoy, Sheryl, Sun, Yu-Nien, Johnson, Jessica, Adewoye, Adeboye H, Price, Timothy
Published 2011

Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?

by Chau, Nicole G, Florescu, Ana, Chan, Kelvin K, Wang, Lisa, Chen, Eric X, Bedard, Philippe, Oza, Amit M, Siu, Lillian L
Published 2011

Pre-Clinical Characterization of Dacomitinib (PF-00299804), an Irreversible Pan-ErbB Inhibitor, Combined with Ionizing Radiation for Head and Neck Squamous Cell Carcinoma

by Williams, Justin P., Kim, Inki, Ito, Emma, Shi, Wei, Yue, Shijun, Siu, Lillian L., Waldron, John, O'Sullivan, Brian, Yip, Kenneth W., Liu, Fei-Fei
Published 2014

The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of...

by Chau, Nicole G, Perez-Ordonez, Bayardo, Zhang, Katherine, Pham, Nhu-An, Ho, James, Zhang, Tong, Ludkovski, Olga, Wang, Lisa, Chen, Eric X, Tsao, Ming-Sound, Kamel-Reid, Suzanne, Siu, Lillian L
Published 2011

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

by Molife, L Rhoda, Yan, Li, Vitfell-Rasmussen, Joanna, Zernhelt, Adriane M, Sullivan, Daniel M, Cassier, Philippe A, Chen, Eric, Biondo, Andrea, Tetteh, Ernestina, Siu, Lillian L, Patnaik, Amita, Papadopoulos, Kyriakos P, de Bono, Johann S, Tolcher, Anthony W, Minton, Susan
Published 2014

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors

by Diaz-Padilla, Ivan, Hirte, Hal, Oza, Amit M., Clarke, Blaise A., Cohen, Brenda, Reedjik, Michael, Zhang, Tong, Kamel-Reid, Suzanne, Ivy, S. Percy, Hotte, Sebastien J., Razak, Albiruni A. R., Chen, Eric X., Brana, Irene, Wizemann, Monika, Wang, Lisa, Siu, Lillian L., Bedard, Philippe L.
Published 2013

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

by Richter, Suzanne, Bedard, Philippe L., Chen, Eric Xueyu, Clarke, Blaise A., Tran, Ben, Hotte, Sebastien J., Stathis, Anastasios, Hirte, Hal W., Razak, Albiruni R. A., Reedijk, Michael, Chen, Zhuo, Cohen, Brenda, Zhang, Wen-Jiang, Wang, Lisa, Ivy, S. Percy, Moore, Malcolm J., Oza, Amit M., Siu, Lillian L., McWhirter, Elaine
Published 2013

A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)

by Chiu, Joanne W., Hotte, Sebastien J., Kollmannsberger, Christian K., Renouf, Daniel J., Cescon, David W., Hedley, David, Chow, Sue, Moscow, Jeffrey, Chen, Zhuo, Perry, Meghan, Diaz-Padilla, Ivan, Tan, David, Hirte, Hal, McWhirter, Elaine, Chen, Helen, Siu, Lillian L., Bedard, Philippe L.
Published 2015

Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies

by Smith, David C., Kalebic, Thea, Infante, Jeffrey R., Siu, Lillian L., Sullivan, Daniel, Vlahovic, Gordana, Kauh, John S., Gao, Feng, Berger, Allison J., Tirrell, Stephen, Gupta, Neeraj, Di Bacco, Alessandra, Berg, Deborah, Liu, Guohui, Lin, Jianchang, Hui, Ai-Min, Thompson, John A.
Published 2015

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

by Stockley, Tracy L., Oza, Amit M., Berman, Hal K., Leighl, Natasha B., Knox, Jennifer J., Shepherd, Frances A., Chen, Eric X., Krzyzanowska, Monika K., Dhani, Neesha, Joshua, Anthony M., Tsao, Ming-Sound, Serra, Stefano, Clarke, Blaise, Roehrl, Michael H., Zhang, Tong, Sukhai, Mahadeo A., Califaretti, Nadia, Trinkaus, Mateya, Shaw, Patricia, van der Kwast, Theodorus, Wang, Lisa, Virtanen, Carl, Kim, Raymond H., Razak, Albiruni R. A., Hansen, Aaron R., Yu, Celeste, Pugh, Trevor J., Kamel-Reid, Suzanne, Siu, Lillian L., Bedard, Philippe L.
Published 2016